Ovarian Cancer

Five-year follow-up data from the SOLO-1 trial continue to show progression-free survival benefit of olaparib as maintenance therapy following platinum-based chemotherapy in the frontline setting for ovarian cancer.

Results of prospective, open-label trial of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer continued to demonstrate efficacy of the PARP inhibitor in this setting.

PFS improvement as well as a trend to overall survival prolongation has been demonstrated with niraparib maintenance in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.

Data from the phase 2 OVARIO study showed extended progression-free survival benefit of niraparib plus bevacizumab in patients with heavily pretreated advanced ovarian cancer.

A dostarlimab triplet combination showed promise in a phase 2 study for treatment of patients with platinum-resistant ovarian cancer, according to a presentation at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer.

An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.

Patients with newly diagnosed ovarian cancer who had interval debulking surgery and visible residual disease showed promising outcomes when treated with the PARP inhibitor niraparib, according to a post hoc analysis of a phase 3 clinical trial.

A bevacizumab-plus-chemotherapy combination improved progression-free survival for a cohort of patients with recurrent platinum-sensitive ovarian cancer, suggesting the potential for a future therapeutic path in clinical practice.

A new drug application for pafolacianine sodium injection was granted priority review by the FDA for use in detecting ovarian cancer lesions during surgical procedures.

In a phase 2 study, adavosertib plus gemcitabine showed signs of activity in platinum-resistant or platinum-refractory advanced high-grade serous ovarian cancer, including rare histological subtypes of ovarian cancer.

Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.

Building off of findings from the phase 3 NOVA study, this study revealed that an individualized starting dose of niraparib based on baseline bodyweight and platelet count could improve the tolerability of niraparib without affecting treatment outcomes.

Data examined the prevalence, risk factors, and prognostic value of chemotherapy-associated venous thromboembolism in patients with ovarian cancer.

Data published in Data in Brief described an analysis that examined palliative care use among different racial and ethnic groups with metastatic gynecologic cancers, including ovarian, cervical, and uterine cancer.

A study of simulated patients with primary epithelial ovarian cancer found that none of the maintenance therapy regimens evaluated were cost-effective when compared with observation following frontline response.

The phase 3 ARIEL4 trial is evaluating rucaparib (Rubraca) versus chemotherapy in patients with platinum-sensitive, partially platinum-sensitive, and platinum-resistant relapsed ovarian cancer and a BRCA mutation who have received 2 or more prior lines of chemotherapy.

A phase 2 trial found that the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.

This study found that the increased risk of ovarian cancer in women treated with assisted reproductive technology compared with the general population can likely be explained by nulliparity instead.

AstraZeneca and Merck announced that the combination treatment of olaparib with bevacizumab to treat adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer was approved in the European Union.

The FDA approved the FoundationOne Liquid CDx for 3 new companion diagnostic indications to help match patients who could benefit from treatment with specific FDA-approved targeted therapies.

A study published in the Annals of Oncology suggests a better method involving tumor gene tests for estimating the survival of women with aggressive ovarian cancers.

The use of PARP inhibitors in frontline maintenance therapy has greatly reduced the risk of recurrence in patients with ovarian cancer.

The phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial indicated that the addition of atezolizumab to bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.